Vivos Therapeutics (VVOS) Other Operating Expenses (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Other Operating Expenses data on file, last reported at -$7.8 million in Q1 2026.

• Quarterly Other Operating Expenses fell 73.44% year-over-year to -$7.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$18.9 million (down 48.35% YoY) and the FY2025 annual result came in at -$21.2 million, down 77.65% from the prior year.
• Other Operating Expenses fell to -$7.8 million in Q1 2026 per VVOS's latest filing, from -$5.8 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $1.7 million in Q2 2022 and bottomed at -$7.8 million in Q1 2026.
• The 5-year median for Other Operating Expenses is $555000.0 (2023), against an average of -$1.4 million.
• Peak annual rise in Other Operating Expenses reached 104.97% in 2025, while the deepest fall reached 737.52% in 2025.
• Tracing VVOS's Other Operating Expenses over 5 years: stood at $1.2 million in 2022, then plunged by 54.66% to $555000.0 in 2023, then plunged by 708.65% to -$3.4 million in 2024, then sank by 71.11% to -$5.8 million in 2025, then tumbled by 34.1% to -$7.8 million in 2026.
• Per Business Quant, the three latest VVOS Other Operating Expenses figures stand at -$7.8 million (Q1 2026), -$5.8 million (Q4 2025), and -$5.5 million (Q3 2025).

Peer Comparison